Connect with us

Politics

Ohio Senate Votes To Expand Marijuana Decriminalization To Cover 200 Grams

Published

on

The Ohio Senate has approved a bill to double the amount of marijuana that is decriminalized in the state and reduce criminal penalties for many other drug crimes.

Following months of delays due to the coronavirus pandemic, the measure cleared both a committee and the full body on Tuesday. The floor vote was 24–5.

While possession of small amounts of cannabis would still be illegal in Ohio, people caught with up to 200 grams of marijuana (about seven ounces) would face no arrest or jail time under the measure, SB 3. Instead, they’d receive a civil citation and pay a fine of $150.

“Among other criminal justice changes, SB 3 would reduce the sentences for several marijuana offenses, including by doubling the amount of marijuana that is decriminalized,” Karen O’Keefe, the Marijuana Policy Project’s director of state policies, told Marijuana Moment.

Existing Ohio law already classifies possession of up to 100 grams (about 3.5 ounces) of marijuana as a “minor misdemeanor.” Offenses are penalized with citations and civil fines of $150. By law, officers are only supposed to arrest people for cannabis if they refuse to provide identification, won’t sign the citation or pose a health and safety risk, but critics note that those exceptions open the door to discriminatory police enforcement.

Under SB 3, simple possession would remain a minor misdemeanor, but the qualifying limits would increase. In addition to the new 200 gram cap for marijuana flower, the limit on hash would rise from 5 grams to 10 grams.

The bill states that citations for those offenses would not constitute a criminal record or need to be reported on “any inquiries contained in any application for employment, license, or other right or privilege.”

Anything over the decriminalized amount limits would still incur criminal penalties, such as arrest, possible jail time and a criminal record. SB 3 would, however, downgrade the criminal designations for greater amounts of cannabis.

For flower, 200 grams to 400 grams would be a fourth-degree misdemeanor under the bill, while 400 to 1,000 grams would be a first-degree misdemeanor. For hash, 10 grams to 20 grams would qualify as a fourth-degree misdemeanor, and 20 grams to 50 grams would be a first-degree misdemeanor.

Possession of other drugs would see downgrades under the bill, too, lessening many felony charges to misdemeanors. Judges in some circumstances would be able to pause criminal cases or even dismiss them entirely for defendants who complete drug treatment programs.

“We believe that we have found the appropriate mark in the sand,” one of the bill’s co-sponsors, state Sen. Sean O’Brien (D), told The Columbus Dispatch a day before the vote.

“I think the overarching goal of the bill is to take small amounts of possession that are clearly for personal use and make that a misdemeanor,” Senate President Larry Obhof (R) said. “That’s really been one of the bigger sticking points over the last year as we’ve considered this. What is really the right amount for personal use versus at what number do we then say, ‘You’re not really using this. You’re a trafficker.’ We’re trying to work that out.”

O’Keefe at Marijuana Policy Project applauded the Senate’s passage of the bill Tuesday but lamented that lawmakers still see cannabis as a police matter at all.

“While these are welcome reforms, Ohio lawmakers should listen to their constituents and legalize marijuana,” she told Marijuana Moment. “There is no need for any police-civilian interaction around simple possession of marijuana. Issuing fines for cannabis possession wastes governmental resources and opens the door to unequal policing and abusive encounters. Ohio should follow Michigan’s lead and legalize, regulate, and tax marijuana for adults.”

Advocates at the beginning of the year intended to put legalization on Ohio’s ballot this November, filing a formal initiative proposal in early March. The effort stalled, however, as the COVID-19 outbreak and resulting social distancing measures made signature gathering all but impossible.

Another group of activists, working to put marijuana decriminalization measures on 14 municipal ballots in Ohio, asked the U.S. Supreme Court to force state officials to allow electronic signature gathering during the pandemic, but the justices did not take up the case.

Ohio voters in 2015 roundly rejected a push to legalize marijuana for adult use, but some think that’s a poor indicator of the state’s interest in legalizing commercial cannabis. The 2015 measure drew criticism at the time even from traditional allies of reform, many of whom criticized the proposal’s licensing provisions that would give a near monopoly on cultivation to the same investors who had funded the ballot initiative.

Despite the slow progress on cannabis reform represented by Senate Bill 3, criminal justice reform advocates praised the bill’s passage by the Senate as a timely response to the issues facing American communities today. Holly Harris, executive director of the Justice Action Network, said the measure “was not written in this moment, but it is the rare bill that is truly meeting the moment.”

“It will help reduce the prison population, leaving far fewer people at risk during the COVID-19 pandemic,” Harris said. “It will save up to $75 million in critical taxpayer dollars as the state deals with a fiscal crisis, and it will eliminate unnecessary interactions with the criminal justice system for minor drug offenses as we work to improve relationships between law enforcement and the communities they serve.”

Colorado Governor Signs Marijuana Social Equity Bill Letting Him Expedite Possession Pardons

Photo courtesy of Max Pixel

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.

Ben Adlin is a Seattle-based writer and editor. He has covered cannabis as a journalist since 2011, most recently as a senior news editor for Leafly.

Politics

Virginia Has Sealed 64,000 Marijuana Distribution Charges Since Legalization Took Effect This Summer

Published

on

“These aren’t just numbers and there are families attached.”

By Ned Oliver, Virginia Mercury

Virginia has sealed records documenting more than 64,000 misdemeanor marijuana distribution charges since the state legalized the drug in July.

The figure came out Thursday during a meeting of the legislature’s Cannabis Oversight Commission.

Officials said the records were scrubbed from the state’s criminal record database, which is used by employers like school boards, state agencies and local governments to screen employees.

The state had already sealed 333,000 records detailing charges of simple possession last year after the state reduced the offense to a civil infraction on par with a traffic offense, said Shawn G. Talmadge, the Deputy Secretary of Public Safety and Homeland Security.

Lawmakers directed the state to expand that effort when they voted to broadly legalize recreational use of marijuana earlier this year.

The legislature also agreed to a broader expungement reform that will automatically seal other misdemeanor charges, including underage possession of alcohol, use of a fake ID, petit larceny, trespassing and disorderly conduct. Talmadge said those charges will remain in the system until the state finishes updating the software it uses to track criminal records.

“As of right now, the process is proceeding,” he said.

Members of the oversight commission also heard from two advocates who urged them to move fast to address people currently imprisoned for marijuana offenses—a category of people the legalization legislation passed this year did not address.

Chelsea Higgs Wise, the leader of the advocacy group Marijuana Justice, and Gracie Burger, with the Last Prisoner Project, said Department of Corrections data suggests there are currently 10 people being held solely on serious marijuana charges.

They said it remains unknown how many more are being held because of marijuana related probation violations.

“These aren’t just numbers and there are families attached,” Burger said.

This story was first published by Virginia Mercury,

Nevada Sold More Than $1 Billion In Marijuana In One Year, Officials Report

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
Continue Reading

Politics

DEA Proposes Dramatic Increase In Marijuana And Psychedelic Production In 2022, Calling For 6,300 Percent More MDMA Alone

Published

on

The Drug Enforcement Administration (DEA) is proposing a dramatic increase in the legal production of marijuana and psychedelics like psilocybin, LSD, MDMA and DMT to be used in research next year.

In a notice scheduled to be published in the Federal Register on Monday, the agency said there’s been a “significant increase in the use of schedule I hallucinogenic controlled substances for research and clinical trial purposes,” and it wants authorized manufacturers to meet that growing demand.

DEA had already massively upped its proposed 2021 quota for cannabis and psilocybin last month, but now it’s calling for significantly larger quantities of research-grade marijuana and a broader array of psychedelics to be manufactured in 2022.

It wants to double the amount of marijuana extracts, psilocybin and psilocyn, quadruple mescaline and quintuple DMT. What especially stands out in the notice is MDMA. The agency is proposing an enormous 6,300 percent boost in the production of that drug—from just 50 grams in 2021 to 3,200 grams in the coming year—as research into its therapeutic potential continues to expand.

LSD would see a 1,150 percent increase, up to 500 grams of the potent psychedelic.

Marijuana itself would get a 60 percent boost under DEA’s proposal, up to 3.2 million grams in 2022 from the 2 million grams last year.

Here’s a visualization of the proposed quota increase from 2021 to 2022 for marijuana and cannabis extracts:

For all other THC, psilocybin, psilocyn and MDMA:

And for other psychedelic substances like LSD, mescaline and DMT:

DEA said in the Federal Register notice that it has been receiving and approving additional applications to “grow, synthesize, extract, and manufacture dosage forms containing specific schedule I hallucinogenic substances for clinical trial purposes” to achieve these ambitious quotas.

“DEA supports regulated research with schedule I controlled substances, as evidenced by increases proposed for 2022 as compared with aggregate production quotas for these substances in 2021,” the agency said, adding that it working “diligently” to process and approve marijuana manufacturers applications in particular, as there’s currently only one farm at the University of Mississippi that’s permitted to cultivate the plant for research.

“Based on the increase in research and clinical trial applications, DEA has proposed increases in 3,4- Methylenedioxyamphetamine (MDA), 3,4-Methylenedioxymethamphetamine (MDMA), 5-Methoxy-N,N-dimethyltryptamine, Dimethyltryptamine, Lysergic acid diethylamide (LSD), Marihuana, Marihuana Extract, Mescaline, Psilocybin, Psilocyn, and All Other Tetrahydrocannabinols to support manufacturing activities related to the increased level of research and clinical trials with these schedule I controlled substances.”

Here are the exact numbers for the proposed 2021 and 2022 quotas:

Substance 2021
2022 proposed
Marijuana 2,000,000 3,200,000
Marijuana extract 500,000 1,000,000
All other tetrahydrocannabinol 1,000 2,000
Psilocybin 1,500 3,000
Psilocyn 1,000 2,000
MDMA 50 3,200
LSD 40 500
Mescaline 25 100
DMT 50 250
5-MeO-DMT 35 550
MDA 55 200

A 30-day public comment period will be open after the notice is formally published on Monday.

It’s difficult to overstate just how significant the proposed 2022 increases are, but it’s certainly true that scientific and public interest in marijuana and psychedelics has rapidly increased, with early clinical trials signaling that such substances show significant therapeutic potential.

National Institute on Drug Abuse (NIDA) Director Nora Volkow told Marijuana Moment in a recent interview that she was encouraged by DEA’s previous proposed increase in drug production quota. She also said that studies demonstrating the therapeutic benefits of psychedelics could be leading more people to experiment with substances like psilocybin.

Advocates and experts remain frustrated that these plants and fungi remain in the strictest federal drug category in the first place, especially considering the existing research that shows their medical value for certain conditions.

A federal appeals court in August dismissed a petition to require the DEA to reevaluate cannabis’s scheduling under the Controlled Substances Act. However, one judge did say in a concurring opinion that the agency may soon be forced to consider a policy change anyway based on a misinterpretation of the therapeutic value of marijuana.

Separately, the Washington State attorney general’s office and lawyers representing cancer patients recently urged a federal appeals panel to push for a DEA policy change to allow people in end-of-life care to access psilocybin under state and federal right-to-try laws.

Singer Melissa Etheridge And Activist Van Jones Promote Psychedelics Reform As Movement Grows

Image element courtesy of Kristie Gianopulos.

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
Continue Reading

Politics

Supreme Court Won’t Hear Case On Legalizing Safe Drug Consumption Sites, But Activists Are Undeterred

Published

on

The U.S. Supreme Court (SCOTUS) has rejected a request to hear a case on the legality of establishing safe injection sites where people can use illicit drugs in a medically supervised environment.

The justices announced on Tuesday that they decided against taking up the case raised by the nonprofit Safehouse, despite the pleas of attorneys general from 10 states and D.C. who recently filed amici briefs urging the court’s involvement.

Representatives from 14 cities and counties, as well as the mayor of Philadelphia, which is at the center of the current case, also filed briefs in support of the case in recent days.

Safehouse was set to launch a safe consumption site in Philadelphia before being blocked by a legal challenge from the Trump administration. It filed a petition with the nation’s highest court in August to hear the case.

But while the Supreme Court declined to take action—and the Biden administration passed up its voluntary opportunity to weigh in at this stage, which may well have influenced the justices’ decision—activists say the battle will continue at a lower federal court level, where the administration will have to file briefs revealing its position on the issue.

“We were disappointed that the government chose not to respond to our petition,” Safehouse Vice President Ronda Goldfein told Filter. “They said, ‘We’re going to waive our right to respond,’ [and] the Supreme Court declined to review our case. Ordinarily that sounds like the end of the road—but in our case we are still pursuing our claims in a different venue.”

That venue will be the the federal district court in Philadelphia, where activists plan to submit multiple arguments related to religious freedom and interstate commerce protections. The Biden administration will be compelled to file a response in that court by November 5.

“If they don’t respond, they lose,” Goldfein said.

A coalition of 80 current and former prosecutors and law enforcement officials—including one who is President Joe Biden’s pick for U.S. attorney of Massachusetts—previously filed a brief urging the Supreme Court to take up Safehouse’s safe injection case.

Fair and Justice Prosecution, the group that coordinated the amicus brief, also organized a tour of Portugal for 20 top prosecutors in 2019 so they could learn about the successful implementation of the country’s drug decriminalization law.

If the Supreme Court were to have taken the case and rule in favor of Safehouse, it could have emboldened advocates and lawmakers across the country to pursue the harm reduction policy.

The governor of Rhode Island signed a bill in July to establish a safe consumption site pilot program where people could test and use currently illicit drugs in a medically supervised environment. It became the first state in the country to legalize the harm reduction centers. It’s not clear whether the Department of Justice will seek to intervene to prevent the opening of such facilities in that state.

Massachusetts lawmakers advanced similar legislation last year, but it was not ultimately enacted.

A similar harm reduction bill in California, sponsored by Sen. Scott Wiener (D), was approved in the state Senate in April, but further action has been delayed until 2022.

Florida Democratic Candidates For Governor Fight Over Who Supports Marijuana Reform The Most

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
Continue Reading
Advertisement

Marijuana News In Your Inbox

Support Marijuana Moment

Marijuana News In Your Inbox

Marijuana Moment